Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $32.14 Consensus Price Target from Analysts
Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 1-year price objective among […]
Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 1-year price objective among […]
